AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study

BACKGROUND: To date, chemotherapy remains the only effective treatment of unresectable pancreatic adenocarcinoma. In the past few years, the interest in immunological anticancer therapy rises sharply. AGIG is a novel chemo-immunotherapy regimen that combines nab-paclitaxel + gemcitabine chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Wangshu, Qiu, Xin, Lu, Changchang, Zou, Zhengyun, Sha, Huizi, Kong, Weiwei, Liu, Baorui, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548663/
https://www.ncbi.nlm.nih.gov/pubmed/34722242
http://dx.doi.org/10.3389/fonc.2021.693386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548663/
https://www.ncbi.nlm.nih.gov/pubmed/34722242
http://dx.doi.org/10.3389/fonc.2021.693386

Ejemplares similares